StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$12.00+0.69 (+6.10%)

Close on Nov 18, 2026Market cap $237.93MP/E –Yield –

Keros Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Keros Therapeutics's pe ratio was 4.8× on Apr 30, 2026.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 20264.8×−8.4
2025Dec 31, 202513.2×–

More Keros Therapeutics figures

See a number that looks wrong?